163 related articles for article (PubMed ID: 1698195)
1. Ribose-transfer activity from uridine to 5-fluorouracil in Ehrlich ascites tumor cells.
Nabeya Y; Isono K; Moriyama Y; Fujimura S
Jpn J Cancer Res; 1990; 81(6-7):692-700. PubMed ID: 1698195
[TBL] [Abstract][Full Text] [Related]
2. Additive formation of antineoplastic 5-fluorouracil nucleosides from 5-fluorouracil by Ehrlich ascites tumor extracts in the presence of ribose 1-phosphate/uridine or deoxyribose 1-phosphate/deoxyuridine.
Tamemasa O; Tezuka M
J Pharmacobiodyn; 1982 Sep; 5(9):720-6. PubMed ID: 7153845
[TBL] [Abstract][Full Text] [Related]
3. Catabolism of 5-fluoro-2'-deoxyuridine by isolated rat intestinal epithelial cells.
Lin FH; Williams WM
Proc Soc Exp Biol Med; 1988 Dec; 189(3):353-61. PubMed ID: 2974595
[TBL] [Abstract][Full Text] [Related]
4. Specificity of pyrimidine nucleoside phosphorylases and the phosphorolysis of 5-fluoro-2'-deoxyuridine.
Woodman PW; Sarrif AM; Heidelberger C
Cancer Res; 1980 Mar; 40(3):507-11. PubMed ID: 6451286
[TBL] [Abstract][Full Text] [Related]
5. A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa.
Peters GJ; van Groeningen CJ; Laurensse EJ; Pinedo HM
Cancer; 1991 Nov; 68(9):1903-9. PubMed ID: 1717130
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of potentiation of antitumor activity of 5-fluorouracil by ribothymidine in a mouse tumor system.
Tezuka M; Chiba Y; Tamemasa O; Okada S
J Pharmacobiodyn; 1986 Dec; 9(12):962-9. PubMed ID: 3572717
[TBL] [Abstract][Full Text] [Related]
7. Role of uridine phosphorylase in the anabolism of 5-fluorouracil.
Schwartz PM; Moir RD; Hyde CM; Turek PJ; Handschumacher RE
Biochem Pharmacol; 1985 Oct; 34(19):3585-9. PubMed ID: 2996553
[TBL] [Abstract][Full Text] [Related]
8. Irreversible enzyme inhibitors. 202. Candidate active-site-directed irreversible inhibitors of 5-fluoro-2'-deoxyuridine phosphorylase from Walker 256 rat tumor derived from 1-benzyl-5-(3-ethoxybenzyl)uracil.
Kelley JL; Baker BR
J Med Chem; 1982 May; 25(5):600-3. PubMed ID: 6211547
[TBL] [Abstract][Full Text] [Related]
9. Enhanced therapeutic efficacy of 5'deoxy-5-fluorouridine in 5-fluorouracil resistant head and neck tumours in relation to 5-fluorouracil metabolising enzymes.
Peters GJ; Braakhuis BJ; de Bruijn EA; Laurensse EJ; van Walsum M; Pinedo HM
Br J Cancer; 1989 Mar; 59(3):327-34. PubMed ID: 2522792
[TBL] [Abstract][Full Text] [Related]
10. The degradation of 5'-deoxy-5-fluorouridine by pyrimidine nucleoside phosphorylase in normal and cancer tissues.
Choong YS; Lee SP
Clin Chim Acta; 1985 Jul; 149(2-3):175-83. PubMed ID: 3161668
[TBL] [Abstract][Full Text] [Related]
11. [Conversion of 5'-deoxy-5-fluorouridine to 5-FU by pyrimidine nucleoside phosphorylases in normal and tumor tissues from rodents bearing tumors and cancer patients].
Miwa M; Nishimura J; Kamiyama T; Ishitsuka H
Gan To Kagaku Ryoho; 1987 Oct; 14(10):2924-9. PubMed ID: 2959206
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of acyclothymidine, a potent pyrimidine nucleoside phosphorylase inhibitor, on the pharmacokinetics of doxifluridine in rabbits via oral administration.
Hamada A; Fukushima S; Morinaga A; Saneyoshi M; Kawaguchi T; Nakano M
Biol Pharm Bull; 1993 Dec; 16(12):1297-300. PubMed ID: 8130783
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of 2,2'-anhydro-5-ethyluridine, a uridine phosphorylase inhibitor, on the antitumor activity of 5-fluorouridine and 5-fluoro-2'-deoxyuridine.
Iigo M; Nishikata K; Nakajima Y; Szinai I; Veres Z; Szabolcs A; De Clercq E
Biochem Pharmacol; 1990 Apr; 39(7):1247-53. PubMed ID: 2138895
[TBL] [Abstract][Full Text] [Related]
14. Metabolism of pyrimidine bases and nucleosides by pyrimidine-nucleoside phosphorylases in cultured human lymphoid cells.
Pérignon JL; Bories DM; Houllier AM; Thuillier L; Cartier PH
Biochim Biophys Acta; 1987 Apr; 928(2):130-6. PubMed ID: 3567226
[TBL] [Abstract][Full Text] [Related]
15. Increased uptake of 5-fluorouracil by Ehrlich ascites tumor cells with some additives and metabolite analysis.
Tezuka M; Chikaraishi Y; Tamemasa O
J Pharmacobiodyn; 1982 Nov; 5(11):893-9. PubMed ID: 6820043
[TBL] [Abstract][Full Text] [Related]
16. Distinguishing between membrane transport and intracellular metabolism of fluorodeoxyuridine in Ehrlich ascites tumor cells by application of kinetic and high performance liquid chromatographic techniques.
Bowen D; Diasio RB; Goldman ID
J Biol Chem; 1979 Jun; 254(12):5333-9. PubMed ID: 156181
[No Abstract] [Full Text] [Related]
17. Increased formation of 5-fluoro-2'-deoxyuridine 5'-monophosphate from 5-fluorouracil in the presence of 2-deoxy-alpha-D-ribose 1-phosphate and 2'-deoxyuridine in Ehrlich ascites tumor cells.
Tamemasa O; Tezuka M
Nucleic Acids Symp Ser; 1980; (8):s169-72. PubMed ID: 7255189
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship of ligands of the pyrimidine nucleoside phosphorylases.
Niedzwicki JG; el Kouni MH; Chu SH; Cha S
Biochem Pharmacol; 1983 Feb; 32(3):399-415. PubMed ID: 6847695
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of intestinal pyrimidine nucleoside phosphorylases.
Wientjes MG; Au JL
Pharm Res; 1987 Oct; 4(5):425-8. PubMed ID: 2977647
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5'-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes.
Peters GJ; Laurensse E; Leyva A; Lankelma J; Pinedo HM
Cancer Res; 1986 Jan; 46(1):20-8. PubMed ID: 2415245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
